POHANKA, Michal, Petr KAŇOVSKÝ, Martin BAREŠ, Jiří PULKRÁBEK and Ivan REKTOR. The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: Results of an open, prospective, six months and one-year follow-up. Česká a slovenská neurologie a neurochirurgie. Česká lékařská společnost J.E.Purkyně, 2005, vol. 68, No 3, p. 164-168. ISSN 1210-7859.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: Results of an open, prospective, six months and one-year follow-up
Name in Czech Dlouhodobé zlepšení sexuální dysfunkce podáváním pergolidu u pacientů v pokročilém stadiu Parkinsovony nemoci- prospektivní 6 měsíční sledování
Authors POHANKA, Michal (203 Czech Republic), Petr KAŇOVSKÝ (203 Czech Republic, guarantor), Martin BAREŠ (203 Czech Republic), Jiří PULKRÁBEK (203 Czech Republic) and Ivan REKTOR (203 Czech Republic).
Edition Česká a slovenská neurologie a neurochirurgie, Česká lékařská společnost J.E.Purkyně, 2005, 1210-7859.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30000 3. Medical and Health Sciences
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 0.070
RIV identification code RIV/00216224:14110/05:00031906
Organization unit Faculty of Medicine
UT WoS 000233791000006
Keywords in English Pergolid; Parkinson disease; treatment; sexual dysfunction
Tags Parkinson disease, pergolid, sexual dysfunction, treatment
Tags International impact, Reviewed
Changed by Changed by: prof. MUDr. Martin Bareš, Ph.D., učo 2002. Changed: 31/3/2010 23:31.
Abstract
The presented study aimed to assess whether the latter effect of pergolide in advanced Parkinson's disease remains stable also in the longer time period. Fourteen male patients suffering from Parkinson's disease, each of whom had been treated with L-DOPA, and in whom additional treatment with peroral dopaminergic agonist (DA) was needed, were followed for a six-months and twelve-months period. Pergolide mesylate (Permax (R)) was given to each patient, and titrated to a total daily dose of 3 mg. All of the patients were taking L-DOPA. There were statistically significant differences between the values of UPDRS III motor subscale, UPDRS IV (complications of therapy) subscale and all subscales of IIEF when months 0 and 1 were compared with the results obtained at months 3, 6 and 12. Pergolide mesylate, when added to L-DOPA, significantly improved sexual functions in younger male patients who were still interested in sexual activities in all aspects.
Abstract (in Czech)
Dlouhodobé zlepšení sexuální dysfunkce podáváním pergolidu u pacientů v pokročilém stadiu Parkinsovony nemoci- prospektivní 6 měsíční sledování
Links
MSM0021622404, plan (intention)Name: Vnitřní organizace a neurobiologické mechanismy funkčních systémů CNS
Investor: Ministry of Education, Youth and Sports of the CR, The internal organisation and neurobiological mechanisms of functional CNS systems under normal and pathological conditions.
PrintDisplayed: 25/5/2024 02:39